Latest news with #Seagen
Globe and Mail
14 hours ago
- Business
- Globe and Mail
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first half of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Oncology sales comprise more than 25% of Pfizer's total revenues. Its oncology revenues grew 9% in the first half of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev, which made up for declining sales of drugs like Ibrance. Xtandi recorded alliance revenues of $566 million in the quarter, up 14% year over year. Lorbrena sales rose 48% to $251 million. Braftovi/Mektovi revenues were $182 million, up 23% year over year. New drug, Elrexfio, generated sales of $85 million in the second quarter. Ibrance revenues declined 8% year over year to $1.05 billion due to continued competitive pressure across markets. Among the ADCs added from the acquisition of Seagen, Adcetris sales were $255 million in the second quarter, which declined 9% year over year due to competitive pressure in the United States. Padcev rose 38% to $542 million, driven by strong demand trends. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars were $353 million in the second quarter, up 27% year over year. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In July, it closed a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology drugs like Padcev, Adcetris and Elrexfio, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Continued growth of Pfizer's diversified portfolio of oncology drugs should support top-line growth in the second half of 2025. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 0.4% so far this year compared with a decrease of 1.2% for the industry. From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.08 forward earnings, lower than 14.45 for the industry and the stock's 5-year mean of 10.78. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $3.05 per share to $3.12 per share, while that for 2026 has gone up from $3.08 to $3.09 per share over the past 30 days. Image Source: Zacks Investment Research Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
14 hours ago
- Business
- Yahoo
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first half of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Oncology sales comprise more than 25% of Pfizer's total revenues. Its oncology revenues grew 9% in the first half of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev, which made up for declining sales of drugs like Ibrance. Xtandi recorded alliance revenues of $566 million in the quarter, up 14% year over year. Lorbrena sales rose 48% to $251 million. Braftovi/Mektovi revenues were $182 million, up 23% year over year. New drug, Elrexfio, generated sales of $85 million in the second quarter. Ibrance revenues declined 8% year over year to $1.05 billion due to continued competitive pressure across markets. Among the ADCs added from the acquisition of Seagen, Adcetris sales were $255 million in the second quarter, which declined 9% year over year due to competitive pressure in the United States. Padcev rose 38% to $542 million, driven by strong demand trends. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars were $353 million in the second quarter, up 27% year over year. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In July, it closed a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology drugs like Padcev, Adcetris and Elrexfio, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Continued growth of Pfizer's diversified portfolio of oncology drugs should support top-line growth in the second half of 2025. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 0.4% so far this year compared with a decrease of 1.2% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.08 forward earnings, lower than 14.45 for the industry and the stock's 5-year mean of 10.78. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $3.05 per share to $3.12 per share, while that for 2026 has gone up from $3.08 to $3.09 per share over the past 30 days. Image Source: Zacks Investment Research Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
Key Points Pfizer's payout ratio is around 90% of earnings, which is high for a dividend stock. It reported strong operational growth of 10% in its most recent quarter. The company continues to focus on cutting costs to improve overall profitability. 10 stocks we like better than Pfizer › Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in such stocks, fearing that those incredibly attractive payouts may not end up being sustainable. One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, which is more than five times what the average rate is for the typical stock on the S&P 500 -- just 1.2%. Could Pfizer be one of the best dividend stocks to add to your portfolio right now, or is its yield too good to be true? Is Pfizer's high payout ratio a concern? A common metric to rely on when evaluating the safety of a dividend stock is its payout ratio. This tells you how much of a company's earnings are being paid out in the form of dividends. The higher it is, the more unsustainable the payout potentially is. Pfizer's payout ratio is currently around 90%, which suggests there isn't a big buffer in its bottom line. However, that number is skewed due to Pfizer's year-end results. In the last three months of 2024, the company incurred billions in asset impairment charges, restructuring expenses, and other non-cash items, which weighed down its earnings. And since the payout ratio looks at a company's earnings over the past 12 months, all it takes is one bad quarter to weigh it down. This is where relying on cash flow can be a better indicator of how healthy a dividend really is. In the trailing 12 months, Pfizer's free cash flow totaled $12.4 billion, which is far higher than the $9.6 billion it paid out in dividends over the past year. This implies the dividend is indeed safe. Recent results suggest the company is going in the right direction As of the end of last week, Pfizer's stock price is down 5% year to date, despite it already taking a beating in previous years. Investors remain concerned about not only its dividend, but also its growth potential. Pfizer is working to reduce costs while also growing its operations. Acquisitions, including its massive $43 billion purchase of oncology company Seagen in 2023, opened up new doors and opportunities for the business that look to be paying off. In its most recent quarter, which ended on June 29, the company reported year-over-year revenue growth of 10%, with sales topping $14.7 billion. Meanwhile, the company continues to reduce costs as it adapts to declining demand for its COVID-19 vaccine and pill. Its diluted earnings per share this past quarter totaled $0.51 -- higher than the rate of its quarterly dividend payment ($0.43). Pfizer's dividend looks safe, and the stock still looks cheap From looking at its financials, there aren't any glaring concerns to suggest that Pfizer's dividend is in trouble. I believe investors are being overly cautious with the stock. And with Pfizer focusing on cost reduction while also still growing its business, it's a top income-generating investment you can own for the long haul. It's currently trading at a price-to-earnings multiple of just 13, making it a fairly cheap stock to own. There are risks for many healthcare companies these days as healthcare reform may impact future profitability, but that can be difficult to predict and forecast. Pfizer is doing an excellent job of managing what it can control, and it's among the best stocks to buy in the healthcare sector. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-08-2025
- Business
- Yahoo
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
For Immediate Release Chicago, IL – August 12, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Novo Nordisk NVO and Eli Lilly LLY. Here are highlights from Monday's Analyst Blog: Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results? Pfizer announced strong second-quarter 2025 results on Aug. 5, beating estimates for both earnings and sales. Adjusted EPS of 78 cents rose 30% year over year while revenues of $14.7 billion were up 10%. Revenues from the Vyndaqel family, Padcev, Lorbrena, Paxlovid and Comirnaty vaccine rose in the quarter. Sales of some other key products like Prevnar, Xeljanz, and Eliquis also improved from first-quarter levels, partially offset by a decline in Ibrance. However, higher manufacturer discounts resulting from the Medicare Part D redesign under the Inflation Reduction Act (IRA) hurt U.S. revenues by $875 million. Pfizer reaffirmed its outlook for revenues for 2025. However, the company raised its adjusted EPS guidance range, despite including a one-time charge related to the 3SBIO transaction. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play Pfizer stock in the post-earnings scenario. PFE Enjoys a Strong Position in Oncology Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen strengthened its position in oncology. Its oncology revenues are rising, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Its oncology revenues grew 9% in the first half of 2025 Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In July, it closed a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. PFE's New Drugs & Seagen Acquisition Driving Top-Line Growth Pfizer's non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen (December 2023). Pfizer's recently launched and acquired products delivered $4.7 billion in revenues in the first half of 2025, rising approximately 15% operationally versus last year. Continued growth of Pfizer's diversified portfolio of drugs, particularly oncology, should support top-line growth in 2025. Pfizer's new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6%. Pfizer expects the acquisition of Seagen to contribute more than $10 billion in 2030 risk-adjusted revenues with potential significant growth beyond 2030. Uncertainty Related to Sales of COVID Products With the end of the pandemic, sales of Pfizer's COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. Though sales of Paxlovid and Comirnaty have stabilized in 2025 after declining significantly in the past two years, their sales are usually weighted toward the second half of the year and are difficult to estimate as they depend on infection rates. There is an element of uncertainty related to COVID sales and they may decline further in future years. Other Headwinds in 2025 Though Pfizer expects a moderate negative impact on revenues from the loss of exclusivity in 2025, the impact is expected to be significant in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. Pfizer expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the IRA, which took effect in the first quarter of 2025. Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA. In April, Pfizer said it is discontinuing the development of its GLP-1R agonist, danuglipron, which was developed as a weight loss pill. Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued. Novo Nordisk and Eli Lilly currently dominate the obesity market with their GLP-1 injections. The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 250%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed. On the Q2 conference call, Pfizer's chief financial officer (CFO), David Denton, said that the company is prepared to mitigate the impact of tariffs in the short term while plans are being devised to help mitigate the potential long-term impact of tariffs on its business operations. President Trump is also trying to implement the Most Favored Nation (MFN) pricing policy. The goal of this proposed policy is to ensure that U.S. consumers pay the same price for some prescription drugs as the nation that pays the lowest price for that drug. Such a policy, if implemented, can hurt prices and reimbursement of some of the company's drugs. PFE's Stock Price, Estimates & Valuation Pfizer's stock has declined 2.4% so far this year compared with a decrease of 6.8% for the industry. From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.93 forward earnings, lower than 13.71 for the industry and the stock's 5-year mean of 10.80. The stock is also much cheaper than other large drugmakers like AbbVie, Novo Nordisk, Lilly, AstraZeneca, J&J and others. The Zacks Consensus Estimate for earnings has risen from $3.07 per share to $3.11 per share for 2025, while that for 2026 has increased from $3.06 per share to $3.09 per share over the past seven days. Stay Invested in PFE Stock Pfizer faces its share of challenges, including COVID-19 product-related uncertainty, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity (LOE) cliff in the 2026-2030 period, uncertainties around tariffs and a volatile macro environment. However, with COVID-related uncertainties diminishing, its revenue volatility is declining. Pfizer's key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer's significant cost reduction and efforts to improve R&D productivity measures should drive profit growth. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth. Pfizer's dividend yield stands at around 7%, which is impressive. In the first half of 2025, Pfizer returned $4.9 billion to shareholders via our quarterly dividend. Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant upside potential. It will be a great pick for value investors, considering its cheap valuation, and for income investors due to its high dividend yield. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
1 Reason to Buy Pfizer (PFE) Stock
Key Points One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's been growing over time. There's reason to be bullish over Pfizer's long-term potential. 10 stocks we like better than Pfizer › I can actually think of multiple reasons to buy shares of Pfizer (NYSE: PFE) stock, but if I had to focus on only one, I'd choose its dividend. The stock's dividend yield was recently a whopping 7.4%! In other words, if you buy at recent levels, you'll collect about $740 each year for every $10,000 you have invested in Pfizer. Invest, say, $30,000, and you're looking at around $2,220 in annual income. And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual dividend amount was recently $1.71 per share, and that's up from $1.52 in 2020 and $1.12 in 2015. Keep in mind, though, that many steep dividend yields are due to the underlying stock having fallen, and Pfizer is a clear example of that phenomenon. Its shares were recently down about 18% over the past year and, in fact, are down even more over the past three years. That's largely due to several patent protections for blockbuster drugs expiring in the coming years, such as patents for Eliquis, Prevnar, and Ibrance. But Pfizer has prepared for that eventuality by building a solid pipeline of drugs in development, some of which could become blockbusters. Partly due to its acquisition of Seagen, Pfizer has become more of a player in oncology, with much of its late-stage drugs in development focused on cancers. Another issue for Pfizer is that sales of its COVID-19 vaccine and its Paxlovid treatment for COVID-19 are down significantly from earlier levels. Still, though, they're on the market and generating revenue for Pfizer. Another green flag for Pfizer is its valuation. Its recent forward-looking price-to-earnings (P/E) ratio of 8 is well below its five-year average of 10, and its price-to-sales ratio, recently 2.1, is well below the five-year average of 3.0. So, give this stock some consideration for your long-term portfolio -- especially if you're interested in dividend income. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Selena Maranjian has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 1 Reason to Buy Pfizer (PFE) Stock was originally published by The Motley Fool
